A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Autor: Neeta Somaiah, Sant P. Chawla, Matthew S. Block, John C. Morris, Khanh Do, Joseph W. Kim, Mihaela Druta, Kamalesh K. Sankhala, Patrick Hwu, Robin L. Jones, Sacha Gnjatic, Seunghee Kim-Schulze, Kevin Tuballes, Mahlet Yishak, Hailing Lu, Adam Yakovich, Jan Ter Meulen, Michael Chen, Richard T. Kenney, Chet Bohac, Seth M. Pollack

Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)

Preclinical data suggest that a “prime-boost” vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a cl

Externí odkaz: https://doaj.org/article/aeaf8cf7e6dc4867be463362683d875c

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Autor: Ahmad S. Halwani, Carlos Panizo, Iris Isufi, Alex F. Herrera, Craig Y. Okada, Elizabeth H. Cull, Bela Kis, Jorge M. Chaves, Nancy L. Bartlett, Weiyun Ai, Luis de la Cruz-Merino, Locke J. Bryan, Roch Houot, Kim Linton, Javier Briones, Ian Chau, Gottfried R. von Keudell, Hailing Lu, Adam Yakovich, Michael Chen, ter Meulen JH, Sergey Yurasov, Frank J. Hsu, Christopher R. Flowers

Publikováno v: Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, ⟨10.1080/10428194.2021.2010057⟩
Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

International audience; Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression. This open-label, multicenter, phase 1/2 trial evaluated the safety,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e37e995b7a7e4fb4d45140e66a7303a
https://doi.org/10.1080/10428194.2021.2010057

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Autor: Joseph Kim, Robin L. Jones, Sant P. Chawla, Mahlet Yishak, Khanh T. Do, Sacha Gnjatic, Kevin Tuballes, Michael Chen, Seunghee Kim-Schulze, Neeta Somaiah, Seth M. Pollack, John C. Morris, Chet Bohac, Richard T. Kenney, Adam Yakovich, Hailing Lu, Kamalesh Kumar Sankhala, Mihaela Druta, Jan ter Meulen, Patrick Hwu, Matthew S. Block

Publikováno v: Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)

Preclinical data suggest that a “prime-boost” vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baee94ef4078ce852f98646f701451d1
https://doi.org/10.1080/2162402x.2020.1847846